A World Health Organization study reports significant drops in child deaths from malaria following the rollout of the pioneering RTS,S vaccine in Ghana, Kenya and Malawi since 2019.
For parents across Kent, the thought of losing a child to preventable disease is unimaginable. Yet for families in sub-Saharan Africa, malaria remains one of the biggest killers of young children. Now, groundbreaking research offers hope that could transform millions of lives.
The Vaccine That Took 30 Years to Develop
RTS,S represents a medical milestone – the world’s first malaria vaccine. After three decades of development, this jab targets children aged 5-17 months, the group most vulnerable to severe malaria. The vaccine works alongside existing prevention methods like insecticide-treated bed nets, not as a replacement.
Starting in 2019, health authorities in Ghana, Kenya and Malawi began rolling out the four-dose vaccine through their routine childhood immunisation programmes. The pilot aimed to answer important questions: would it work in real-world conditions? Could health systems deliver it effectively? Would communities accept it?
The results speak volumes. By April 2021, over 1.7 million doses had reached more than 650,000 children across the three countries. Community demand proved strong, with parents queuing to protect their little ones.
Funding and Global Support
The initial pilot phase cost £39 million, funded by Gavi, the Global Fund and UNITAID between 2017 and 2020. British pharmaceutical giant GSK provided additional support, having developed the vaccine over decades of research.
Dr Kate O’Brien from WHO emphasised that the vaccine complements existing tools rather than replacing them. The organisation’s strategy expanded in 2023 to recommend broader rollouts, above all when combined with seasonal malaria prevention programmes.
Recent trials in Burkina Faso and Mali show even more promise. When RTS,S combines with seasonal chemoprevention, clinical episodes, hospital admissions and deaths drop by about 70%.
Expanding Reach
Success breeds expansion. As of August 2025, 22 countries have introduced the malaria vaccine, building on lessons learned from the original three-country pilot. Post-introduction evaluations conducted in 2021 helped refine delivery methods and inform wider rollouts.
The vaccine represents hope for regions where malaria, caused by Plasmodium parasites, continues claiming young lives. For these communities, RTS,S offers protection that was unimaginable just a few years ago.
Source: @bmj_latest
Key Takeaways
- Over 1.7 million RTS,S vaccine doses reached more than 650,000 children in Ghana, Kenya and Malawi by April 2021
- The world’s first malaria vaccine shows significant reductions in child mortality when integrated into routine immunisation programmes
- 22 countries have now introduced the vaccine, with strong community demand and effective delivery systems
What This Means for Kent Residents
While malaria vaccination isn’t needed here in Kent, residents planning travel to sub-Saharan Africa should take precautions seriously. Anyone heading to malaria-risk areas should consult their GP or contact NHS Kent and Medway ICB for antimalarial prophylaxis advice well before departure. The RTS,S vaccine isn’t available in the UK, making prevention through medication and protective measures essential for Kent travellers visiting affected regions.